Developer docs
API playgroundTry for free, no card

Search company profiles

Novavax

Full company profile

uuid0000aun

Namestring
Novavax
Legal namestring
Novavax, Inc.
Websiteurl
novavax.com
Company typeenum
Public
Founded yearint
1987
Descriptiontext

Novavax is a publicly traded biotechnology company (NASDAQ: NVAX) founded in 1987 and headquartered in Gaithersburg, Maryland, that develops vaccines built on two proprietary technology platforms: recombinant protein-based nanoparticles that mimic target pathogen antigens, and the Matrix-M saponin-based adjuvant, derived from soapbark tree compounds, which enhances the magnitude and duration of immune response. Its marketed portfolio consists of Nuvaxovid (a COVID-19 vaccine whose U.S. and EU commercial rights have been transferred to Sanofi) and the R21/Matrix-M malaria vaccine distributed by the Serum Institute of India, which has achieved over 80% market share with 30 million doses sold since mid-2024. The company also operates a Sweden-based R&D unit in Uppsala (Novavax Sweden) housing the Matrix-M inventor Karin Lövgren Bengtsson, and has a U.S. headquarters plus a former Czech manufacturing facility sold to Novo Nordisk in 2025 for $200 million.

Following the COVID-19 pandemic, Novavax executed a strategic pivot from a vertically integrated vaccine manufacturer to a partnership-driven adjuvant and technology licensing platform. Revenue is generated through four streams: direct Nuvaxovid product sales under legacy APA and commercial agreements (declining as Sanofi assumes commercial responsibility); supply sales of finished product and Matrix-M adjuvant to license partners (Sanofi, Takeda, Serum Institute); licensing, royalties, and milestone payments (Sanofi $1.2B deal, Pfizer $530M Matrix-M license announced January 2026 with $30M upfront and up to $500M in milestones); and R&D reimbursements under the Sanofi co-exclusive licensing agreement (expected $70-80M in 2026). Customer segments include pharmaceutical partners licensing Matrix-M for vaccine development across infectious diseases and oncology, adults 65+ and high-risk populations for COVID-19 vaccination, and global health/malaria programs through the R21/Matrix-M partnership. The company employs 501-1,000 people and is led by President and CEO John C. Jacobs, with Dr. Robert Walker appointed as EVP and Head of R&D in March 2026.

Short descriptiontext

Novavax (NASDAQ: NVAX) is a biotechnology company that develops protein nanoparticle vaccines and licenses its proprietary Matrix-M adjuvant to major pharmaceutical partners (Sanofi, Pfizer, Takeda, Serum Institute) across infectious disease and oncology applications, with marketed products including Nuvaxovid and R21/Matrix-M malaria vaccine.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersGaithersburg, United States
HQ citystring
Gaithersburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
vaccine development, adjuvant technology licensing, protein nanoparticle vaccines, infectious disease prevention, biotechnology partnerships
Industry3 codes
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Vaccines
Social media profiles3 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Nuvaxovid Product Sales
TypeOne Time License
Description

Direct product sales of Nuvaxovid COVID-19 vaccine where Novavax is commercial market lead. Revenue declining as responsibility transitions to Sanofi.

ir.novavax.com
2Supply Sales
TypeTransaction Fee
Description

Sales of finished product, adjuvant, and other supplies from Novavax to its license partners including Sanofi, Takeda, and Serum Institute.

ir.novavax.com
3Licensing, Royalties and Milestones
TypeLicensing Royalties
Description

Revenue from license agreements including upfront payments, milestones, and royalties. Includes $30M Pfizer upfront, Sanofi milestones ($225M earned in 2025), and tiered royalties on partner product sales.

ir.novavax.com
4R&D Reimbursements
TypeManaged Services
Description

Under Sanofi co-exclusive licensing agreement, Novavax receives reimbursement for costs related to select R&D and technology transfer activities during transition period. $70-80M expected in 2026.

ir.novavax.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Nuvaxovid product sales under existing APA and commercial agreements
ModelOne time/ perpetual licenseBilling cadenceMulti-year contract
Notes

$35-45 million expected in 2026 product sales

ir.novavax.com
2Supply sales to partners
ModelUnit PricingBilling cadenceMulti-year contract
Notes

$40-50 million expected in 2026 supply sales

ir.novavax.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Matrix-M
Description

Proprietary saponin-based adjuvant technology that enhances immune response in vaccines

novavax.com
+2 more records
Core offering1 text field

Novavax is a biotechnology company that develops and commercializes vaccines built on its proprietary Matrix-M saponin-based adjuvant combined with recombinant protein nanoparticle antigens. It markets Nuvaxovid (COVID-19) and R21/Matrix-M (malaria, with Serum Institute), while monetizing the Matrix-M platform primarily through licensing deals, milestone payments, and royalties with pharmaceutical partners including Sanofi, Pfizer, and Takeda.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • R21/Matrix-M malaria vaccine achieved 80%+ market share with 30 million doses sold since mid-2024 launch
+2 more records
Product overview1 text field

Novavax is a biotechnology company focused on vaccine development with a proprietary technology platform combining Matrix-M adjuvant and protein-based nanoparticles. The marketed product portfolio includes Nuvaxovid (COVID-19 vaccine, with commercial rights transferred to Sanofi) and R21/Matrix-M malaria vaccine (partnered with Serum Institute). The company generates revenue through licensing its Matrix-M technology to major pharmaceutical partners including Sanofi, Pfizer, and Takeda. The pipeline includes COVID-19-influenza combination vaccines, standalone influenza vaccine, C. difficile vaccine, shingles vaccine, and RSV vaccine candidates, all leveraging the Matrix-M adjuvant platform.

Product and service9 records
1Matrix-M Adjuvant Technology
CategoryTechnology Platform / Adjuvant
Description

Proprietary saponin-based adjuvant technology that enhances the magnitude and duration of immune response in vaccines. Licensed to Sanofi, Pfizer, Takeda, and other pharmaceutical partners for use across infectious disease and oncology vaccine development. Novavax manufactures and supplies the adjuvant while partners handle product development and commercialization.

2Nuvaxovid (NVX-CoV2373) COVID-19 Vaccine
CategoryMarketed Vaccine Product
Description

Protein-based COVID-19 vaccine combining recombinant nanoparticle antigen (NVX-CoV2373) with Matrix-M adjuvant. Commercialized by Sanofi in the U.S. and EU, by Takeda in Japan, and supplied to government vaccination programs including Singapore's National Vaccination Programme.

3R21/Matrix-M Malaria Vaccine
CategoryMarketed Vaccine Product
Description

Malaria vaccine leveraging Matrix-M adjuvant technology, developed and commercialized with Serum Institute of India. Indicated for prevention of P. falciparum malaria in children in endemic regions including Africa; supplied through COVAX and global health channels.

4COVID-19-Influenza Combination Vaccine
CategoryPipeline Vaccine Product
Description

Combined COVID-19 and influenza vaccine candidate in Phase 3 development, leveraging Matrix-M adjuvant with recombinant nanoparticle antigens. Sanofi is advancing toward regulatory filing with potential 2027-2028 approval.

5Stand-alone Influenza Vaccine
CategoryPipeline Vaccine Product
Description

Recombinant quadrivalent influenza vaccine candidate in Phase 3 development using Matrix-M adjuvant technology.

6C. difficile Vaccine Candidate
CategoryPipeline Vaccine Product
Description

Clostridioides difficile colitis vaccine candidate in preclinical development, leveraging Novavax's recombinant nanoparticle and Matrix-M adjuvant platform. Identified as a potential next asset to enter clinical trials.

7Varicella-Zoster Virus (Shingles) Vaccine Candidate
CategoryPipeline Vaccine Product
Description

Preclinical vaccine candidate targeting shingles (Varicella-Zoster Virus) using Novavax's recombinant nanoparticle and Matrix-M adjuvant platform.

8RSV Vaccine Candidates
CategoryPipeline Vaccine Product
Description

Respiratory syncytial virus (RSV) vaccine candidates in early-stage development leveraging Novavax's Matrix-M adjuvant technology.

9H5N1 Vaccine Candidate
CategoryPipeline Vaccine Product
Description

Preclinical H5N1 avian influenza vaccine candidate that has demonstrated immunogenicity against currently circulating H5N1 variants in preclinical studies using Matrix-M adjuvant technology.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2026-01-20
Description

Non-exclusive license agreement granting Pfizer rights to use Matrix-M adjuvant technology for up to two infectious disease vaccine programs. Novavax receives $30 million upfront with potential for up to $500 million in development and sales milestones, plus high mid-single digit percentage royalties. Pfizer controls development and commercialization while Novavax supplies Matrix-M.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

$1.2 billion licensing deal for commercialization of Nuvaxovid and Matrix-M technology. Sanofi took over US and EU marketing authorization in late 2024. Novavax earned $225 million in milestones in 2025. Sanofi developing COVID-flu combination vaccine with potential 2027-2028 approval. Novavax eligible for up to $350 million in Phase 3 and launch milestones plus royalties.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Takeda manufactures and commercializes Nuvaxovid in Japan. Achieved 12% market share in Japan. Takeda triggered milestone payment following regulatory approval of the COVID-19 vaccine in Japan.

Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Manufacturing and distribution partner for R21/Matrix-M malaria vaccine. 30 million doses sold since mid-2024 launch, achieving over 80% market share. Major supplier for COVAX and global malaria prevention efforts.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

$85 million equity investment acquiring 6.5 million shares. Extended license agreement for COVID-19 variant vaccine rights in South Korea, Thailand, and Vietnam. Partnership shifting from pandemic-focused to endemic-focused response.

6Material Transfer Agreement Partners
Strategic tierSecondaryTypeTechnology or Integration
Description

Multiple MTAs with pharmaceutical companies exploring Matrix-M utility across over 30 fields of experimentation including infectious diseases and oncology. Includes top 10 global pharma and oncology-focused companies. Goal is to convert MTAs into deeper licensing partnerships.

ir.novavax.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global influenza vaccine leader and a competitor in the seasonal flu space where Novavax is advancing a Matrix-M-adjuvanted standalone flu vaccine through Phase 3 with Sanofi.

TypeDirect peer
Description

Directly comparable COVID-19 vaccine developer that competes head-to-head with Novavax's Nuvaxovid in the US, EU, and other markets, and is now advancing a similar COVID-influenza combination vaccine strategy.

TypeDirect peer
Description

Co-developer of the Pfizer-BioNTech COVID-19 vaccine and a direct competitor to Nuvaxovid in the protein-subunit vs mRNA vaccine market, with overlapping infectious disease pipeline ambitions.

TypeDirect peer
Description

Adjuvant-focused vaccine company whose CpG 1018 adjuvant competes with Novavax's Matrix-M for inclusion in partner vaccines; comparable business model built around licensing an adjuvant technology platform.

5Valneva
TypeDirect peer
Description

Specialty vaccine developer focused on travel and endemic infectious diseases with a similar mid-cap, partnership-driven commercialization model targeting comparable disease areas.

TypeDirect peer
Description

Mid-cap vaccine company with comparable scale and partnership-based commercialization, focused on infectious disease and oncology vaccines that could leverage adjuvanted technology.

TypeBroad incumbent
Description

Top-10 global pharmaceutical company and Novavax's largest commercialization partner for Nuvaxovid and Matrix-M; comparable as a major vaccine incumbent with broad infectious disease portfolio and the partnership economics dictate much of Novavax's near-term value.

TypeBroad incumbent
Description

Top-10 global pharmaceutical company and Matrix-M licensee as of January 2026; comparable as a vaccine incumbent whose own COVID-19 franchise competes with Nuvaxovid while its licensing agreement creates upside for Novavax.

TypeBroad incumbent
Description

Global vaccine leader with adjuvant expertise (AS01 system) and broad infectious disease portfolio; comparable as an incumbent developing and commercializing adjuvanted vaccines that could compete with or complement Matrix-M-partnered products.

TypeEmerging player
Description

Mid-cap vaccine/biodefense company with comparable scale and a focus on infectious disease vaccines, including adjuvanted candidates that overlap with Novavax's pipeline in C. difficile and other indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds13 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Novavax

Vaccinesnovavax.com

Novavax (NASDAQ: NVAX) is a biotechnology company that develops protein nanoparticle vaccines and licenses its proprietary Matrix-M adjuvant to major pharmaceutical partners (Sanofi, Pfizer, Takeda, Serum Institute) across infectious disease and oncology applications, with marketed products including Nuvaxovid and R21/Matrix-M malaria vaccine.

What Novavax does

Novavax is a publicly traded biotechnology company (NASDAQ: NVAX) founded in 1987 and headquartered in Gaithersburg, Maryland, that develops vaccines built on two proprietary technology platforms: recombinant protein-based nanoparticles that mimic target pathogen antigens, and the Matrix-M saponin-based adjuvant, derived from soapbark tree compounds, which enhances the magnitude and duration of immune response. Its marketed portfolio consists of Nuvaxovid (a COVID-19 vaccine whose U.S. and EU commercial rights have been transferred to Sanofi) and the R21/Matrix-M malaria vaccine distributed by the Serum Institute of India, which has achieved over 80% market share with 30 million doses sold since mid-2024. The company also operates a Sweden-based R&D unit in Uppsala (Novavax Sweden) housing the Matrix-M inventor Karin Lövgren Bengtsson, and has a U.S. headquarters plus a former Czech manufacturing facility sold to Novo Nordisk in 2025 for $200 million.

Following the COVID-19 pandemic, Novavax executed a strategic pivot from a vertically integrated vaccine manufacturer to a partnership-driven adjuvant and technology licensing platform. Revenue is generated through four streams: direct Nuvaxovid product sales under legacy APA and commercial agreements (declining as Sanofi assumes commercial responsibility); supply sales of finished product and Matrix-M adjuvant to license partners (Sanofi, Takeda, Serum Institute); licensing, royalties, and milestone payments (Sanofi $1.2B deal, Pfizer $530M Matrix-M license announced January 2026 with $30M upfront and up to $500M in milestones); and R&D reimbursements under the Sanofi co-exclusive licensing agreement (expected $70-80M in 2026). Customer segments include pharmaceutical partners licensing Matrix-M for vaccine development across infectious diseases and oncology, adults 65+ and high-risk populations for COVID-19 vaccination, and global health/malaria programs through the R21/Matrix-M partnership. The company employs 501-1,000 people and is led by President and CEO John C. Jacobs, with Dr. Robert Walker appointed as EVP and Head of R&D in March 2026.

Novavax firmographics

Firmographics
Name
Novavax
Legal name
Novavax, Inc.
Website
https://novavax.com
Company type
Public
Founded year
1987
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Novavax (NASDAQ: NVAX) is a biotechnology company that develops protein nanoparticle vaccines and licenses its proprietary Matrix-M adjuvant to major pharmaceutical partners (Sanofi, Pfizer, Takeda, Serum Institute) across infectious disease and oncology applications, with marketed products including Nuvaxovid and R21/Matrix-M malaria vaccine.
Ownership category
akta.pro rank

Novavax industry classification

Industry
Product category
Vaccines
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAAAKAD
Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral)

Keywords

  • Vaccine development
  • Adjuvant technology licensing
  • Protein nanoparticle vaccines
  • Infectious disease prevention
  • Biotechnology partnerships

Where Novavax is headquartered

Location

Headquarters

HQ city
Gaithersburg
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Novavax business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

  1. Nuvaxovid Product Sales: Direct product sales of Nuvaxovid COVID-19 vaccine where Novavax is commercial market lead. Revenue declining as responsibility transitions to Sanofi.
  2. Supply Sales: Sales of finished product, adjuvant, and other supplies from Novavax to its license partners including Sanofi, Takeda, and Serum Institute.
  3. Licensing, Royalties and Milestones: Revenue from license agreements including upfront payments, milestones, and royalties. Includes $30M Pfizer upfront, Sanofi milestones ($225M earned in 2025), and tiered royalties on partner product sales.
  4. R&D Reimbursements: Under Sanofi co-exclusive licensing agreement, Novavax receives reimbursement for costs related to select R&D and technology transfer activities during transition period. $70-80M expected in 2026.

Pricing tiers

ModelBillingPrice
One time/ perpetual licenseMulti-year contractNuvaxovid product sales under existing APA and commercial agreements
Unit PricingMulti-year contractSupply sales to partners

Go-to-market motion2 records

Distribution channels4 records

Marketing channels4 records

Novavax product offering

Product offering

Core offering

Novavax is a biotechnology company that develops and commercializes vaccines built on its proprietary Matrix-M saponin-based adjuvant combined with recombinant protein nanoparticle antigens. It markets Nuvaxovid (COVID-19) and R21/Matrix-M (malaria, with Serum Institute), while monetizing the Matrix-M platform primarily through licensing deals, milestone payments, and royalties with pharmaceutical partners including Sanofi, Pfizer, and Takeda.

Product overview

Novavax is a biotechnology company focused on vaccine development with a proprietary technology platform combining Matrix-M adjuvant and protein-based nanoparticles. The marketed product portfolio includes Nuvaxovid (COVID-19 vaccine, with commercial rights transferred to Sanofi) and R21/Matrix-M malaria vaccine (partnered with Serum Institute). The company generates revenue through licensing its Matrix-M technology to major pharmaceutical partners including Sanofi, Pfizer, and Takeda. The pipeline includes COVID-19-influenza combination vaccines, standalone influenza vaccine, C. difficile vaccine, shingles vaccine, and RSV vaccine candidates, all leveraging the Matrix-M adjuvant platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Matrix-M: Proprietary saponin-based adjuvant technology that enhances immune response in vaccines
  • Nuvaxovid
  • R21/Matrix-M

Products and services

  • Matrix-M Adjuvant Technology Proprietary saponin-based adjuvant technology that enhances the magnitude and duration of immune response in vaccines. Licensed to Sanofi, Pfizer, Takeda, and other pharmaceutical partners for use across infectious disease and oncology vaccine development. Novavax manufactures and supplies the adjuvant while partners handle product development and commercialization.
  • Nuvaxovid (NVX-CoV2373) COVID-19 Vaccine Protein-based COVID-19 vaccine combining recombinant nanoparticle antigen (NVX-CoV2373) with Matrix-M adjuvant. Commercialized by Sanofi in the U.S. and EU, by Takeda in Japan, and supplied to government vaccination programs including Singapore's National Vaccination Programme.
  • R21/Matrix-M Malaria Vaccine Malaria vaccine leveraging Matrix-M adjuvant technology, developed and commercialized with Serum Institute of India. Indicated for prevention of P. falciparum malaria in children in endemic regions including Africa; supplied through COVAX and global health channels.
  • COVID-19-Influenza Combination Vaccine Combined COVID-19 and influenza vaccine candidate in Phase 3 development, leveraging Matrix-M adjuvant with recombinant nanoparticle antigens. Sanofi is advancing toward regulatory filing with potential 2027-2028 approval.
  • Stand-alone Influenza Vaccine Recombinant quadrivalent influenza vaccine candidate in Phase 3 development using Matrix-M adjuvant technology.
  • C. difficile Vaccine Candidate Clostridioides difficile colitis vaccine candidate in preclinical development, leveraging Novavax's recombinant nanoparticle and Matrix-M adjuvant platform. Identified as a potential next asset to enter clinical trials.
  • Varicella-Zoster Virus (Shingles) Vaccine Candidate Preclinical vaccine candidate targeting shingles (Varicella-Zoster Virus) using Novavax's recombinant nanoparticle and Matrix-M adjuvant platform.
  • RSV Vaccine Candidates Respiratory syncytial virus (RSV) vaccine candidates in early-stage development leveraging Novavax's Matrix-M adjuvant technology.
  • H5N1 Vaccine Candidate Preclinical H5N1 avian influenza vaccine candidate that has demonstrated immunogenicity against currently circulating H5N1 variants in preclinical studies using Matrix-M adjuvant technology.

Quantifiable outcome

  • R21/Matrix-M malaria vaccine achieved 80%+ market share with 30 million doses sold since mid-2024 launch
  • +2 more outcomes

Companies that use Novavax

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Novavax technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Novavax partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core, flagship and secondary.

  • PfizercoreOEM/ Whitelabel/ Licensing Partner · 20 January 2026Non-exclusive license agreement granting Pfizer rights to use Matrix-M adjuvant technology for up to two infectious disease vaccine programs. Novavax receives $30 million upfront with potential for up to $500 million in development and sales milestones, plus high mid-single digit percentage royalties. Pfizer controls development and commercialization while Novavax supplies Matrix-M.
  • SanofiflagshipStrategic or Co-development Partner$1.2 billion licensing deal for commercialization of Nuvaxovid and Matrix-M technology. Sanofi took over US and EU marketing authorization in late 2024. Novavax earned $225 million in milestones in 2025. Sanofi developing COVID-flu combination vaccine with potential 2027-2028 approval. Novavax eligible for up to $350 million in Phase 3 and launch milestones plus royalties.
  • TakedacoreChannel Partner/ Reseller/ DistributorTakeda manufactures and commercializes Nuvaxovid in Japan. Achieved 12% market share in Japan. Takeda triggered milestone payment following regulatory approval of the COVID-19 vaccine in Japan.
  • Serum Institute of IndiacoreChannel Partner/ Reseller/ DistributorManufacturing and distribution partner for R21/Matrix-M malaria vaccine. 30 million doses sold since mid-2024 launch, achieving over 80% market share. Major supplier for COVAX and global malaria prevention efforts.
  • SK biosciencesecondaryStrategic or Co-development Partner$85 million equity investment acquiring 6.5 million shares. Extended license agreement for COVID-19 variant vaccine rights in South Korea, Thailand, and Vietnam. Partnership shifting from pandemic-focused to endemic-focused response.
  • Material Transfer Agreement PartnerssecondaryTechnology or IntegrationMultiple MTAs with pharmaceutical companies exploring Matrix-M utility across over 30 fields of experimentation including infectious diseases and oncology. Includes top 10 global pharma and oncology-focused companies. Goal is to convert MTAs into deeper licensing partnerships.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Novavax competitors and assessment

Company assessment

Broad incumbents

  • CSL Seqirus: Global influenza vaccine leader and a competitor in the seasonal flu space where Novavax is advancing a Matrix-M-adjuvanted standalone flu vaccine through Phase 3 with Sanofi.
  • Sanofi: Top-10 global pharmaceutical company and Novavax's largest commercialization partner for Nuvaxovid and Matrix-M; comparable as a major vaccine incumbent with broad infectious disease portfolio and the partnership economics dictate much of Novavax's near-term value.
  • Pfizer: Top-10 global pharmaceutical company and Matrix-M licensee as of January 2026; comparable as a vaccine incumbent whose own COVID-19 franchise competes with Nuvaxovid while its licensing agreement creates upside for Novavax.
  • GSK: Global vaccine leader with adjuvant expertise (AS01 system) and broad infectious disease portfolio; comparable as an incumbent developing and commercializing adjuvanted vaccines that could compete with or complement Matrix-M-partnered products.

Direct peers

  • Moderna: Directly comparable COVID-19 vaccine developer that competes head-to-head with Novavax's Nuvaxovid in the US, EU, and other markets, and is now advancing a similar COVID-influenza combination vaccine strategy.
  • BioNTech: Co-developer of the Pfizer-BioNTech COVID-19 vaccine and a direct competitor to Nuvaxovid in the protein-subunit vs mRNA vaccine market, with overlapping infectious disease pipeline ambitions.
  • Dynavax Technologies: Adjuvant-focused vaccine company whose CpG 1018 adjuvant competes with Novavax's Matrix-M for inclusion in partner vaccines; comparable business model built around licensing an adjuvant technology platform.
  • Valneva: Specialty vaccine developer focused on travel and endemic infectious diseases with a similar mid-cap, partnership-driven commercialization model targeting comparable disease areas.
  • Bavarian Nordic: Mid-cap vaccine company with comparable scale and partnership-based commercialization, focused on infectious disease and oncology vaccines that could leverage adjuvanted technology.

Emerging players

  • Emergent BioSolutions: Mid-cap vaccine/biodefense company with comparable scale and a focus on infectious disease vaccines, including adjuvanted candidates that overlap with Novavax's pipeline in C. difficile and other indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

Novavax social profiles

Digital presence

Novavax financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Novavax leadership team

Management profile

Number of profiles

Profiles4 records

Novavax subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Novavax funding detail

Funding detail

Funding overview

Funding rounds13 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Novavax M&A and investment

M&A and investment

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Novavax

What does Novavax do?

Novavax is a biotechnology company that develops and commercializes vaccines built on its proprietary Matrix-M saponin-based adjuvant combined with recombinant protein nanoparticle antigens. It markets Nuvaxovid (COVID-19) and R21/Matrix-M (malaria, with Serum Institute), while monetizing the Matrix-M platform primarily through licensing deals, milestone payments, and royalties with pharmaceutical partners including Sanofi, Pfizer, and Takeda.

Is Novavax a public or private company?

Novavax is a public company. It is classified as public and is currently operating.

When was Novavax founded?

Novavax was founded in 1987. It employs 501 to 1,000 people.

Where is Novavax based?

Novavax is headquartered in Gaithersburg, United States, in the North America region.

How does Novavax make money?

Four revenue lines are on record. Nuvaxovid Product Sales are the primary driver. The others are supply Sales, licensing, Royalties and Milestones and R&D Reimbursements.

Who are Novavax's main competitors?

Broad incumbents on record are CSL Seqirus, Sanofi, Pfizer and GSK. Direct peers are Moderna, BioNTech, Dynavax Technologies, Valneva and Bavarian Nordic. Emergent BioSolutions is listed as an emerging player.

Does Novavax have an API?

No public API is recorded for Novavax.

What industry is Novavax in?

Novavax's product category is Vaccines. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchNovavax Inc. stock outperforms competitors despite losses on the dayNovavax Inc. shares fell 1.24% to $7.96 on Tuesday, marking the sixth consecutive day of losses. The decline occurred amid a rough trading session, with the NASDAQ Composite down 0.74% and the Dow down 1.64%.MarketBeatNovavax Eyes New Partnerships as Sanofi Advances COVID-Flu Vaccine TrialNovavax executives at the Jefferies 2026 conference said the company is shifting to licensing its vaccine technology, citing a $30 million upfront deal with Pfizer and a $125 million milestone after Sanofi's combination vaccine trial. Sanofi will start a Phase 3 U.S. study in 2027, with Novavax potentially earning $225 million if the vaccine achieves a first U.S. sale.TradingViewNVAX: Partner-led vaccine programs and cost discipline underpin a broad 2027 catalyst slateNovavax's strategy centers on licensing Matrix-M, deepening partnerships, and advancing a C. difficile vaccine toward a possible 2027 trial. Sanofi's combination program and disciplined financial targets anchor the near-term outlook.Investing.comNovavax at Jefferies Global Healthcare Conference: partnerships drive resetNovavax outlined a partnership-led reset at the Jefferies Global Healthcare Conference, shifting from a single COVID vaccine to a platform business. It highlighted a $500 million Pfizer deal and a $125 million Sanofi milestone for a combination COVID-flu vaccine, with a U.S. trial planned for 2027. The company targets non-GAAP profitability by 2029.MarketWatchNovavax Inc. stock underperforms Monday when compared to competitorsNovavax Inc. shares fell 5.45% to $8.06 on Monday, marking the fifth consecutive day of losses. The decline occurred amid a broader market downturn, with the NASDAQ Composite down 2.49% and the Dow down 1.41%.Simply Wall StWhat Novavax Buyers Were Betting OnNovavax shares rose 22.3% over the past year, with Q3 2026 showing a $31.4M loss but improved net margin. The stock's valuation hinges on Matrix M licensing royalties and Sanofi milestones through 2029, while partner revenue share and profitability remain unproven.PrwebThe Healthcare Technology Report Announces The Top Biotech and Life Sciences Companies of 2026The Healthcare Technology Report announced its 2026 Top Biotech and Life Sciences Companies, including Celcuity, Summit Therapeutics, Novavax, and Orano Med. Highlights include Celcuity's FDA approval for REVTORPYK, Summit's Phase 3 lung cancer data and $2 billion AstraZeneca investment, and Novavax's Pfizer licensing deal.MarketWatchNovavax Inc. stock underperforms Friday when compared to competitorsNovavax Inc. shares fell 2.68% to $8.53 on Friday, marking its fourth consecutive day of losses. The Dow rose 0.10% to 52,347.55 while the NASDAQ fell 0.91% to 25,136.27.MarketWatchNovavax Inc. stock underperforms Thursday when compared to competitorsNovavax Inc. shares fell 12.22% to $8.76 on Thursday, marking the third consecutive day of losses. The decline occurred amid a rough trading session, with the NASDAQ Composite down 0.39% and the Dow down 0.36%.MarketWatchNovavax Inc. stock underperforms Wednesday when compared to competitorsNovavax Inc. shares fell 2.16% to $9.98 on Wednesday, marking a second consecutive day of losses. The decline occurred despite a strong market session, with the NASDAQ rising 1.60% and the Dow up 0.49%.